BE879489A - Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation - Google Patents
Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation Download PDFInfo
- Publication number
- BE879489A BE879489A BE0/197705A BE197705A BE879489A BE 879489 A BE879489 A BE 879489A BE 0/197705 A BE0/197705 A BE 0/197705A BE 197705 A BE197705 A BE 197705A BE 879489 A BE879489 A BE 879489A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- acid
- pharmaceutical composition
- composition according
- strains
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 238000000034 method Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 19
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 12
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960000210 nalidixic acid Drugs 0.000 claims description 11
- 229960000321 oxolinic acid Drugs 0.000 claims description 11
- 229950006669 cefalexin pivoxil Drugs 0.000 claims description 9
- DIGADQKVPFDJSI-SPYBWZPUSA-N cefalexin pivoxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DIGADQKVPFDJSI-SPYBWZPUSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229960001732 pipemidic acid Drugs 0.000 claims description 5
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004444 piromidic acid Drugs 0.000 claims description 4
- ACXMTAJLYQCRGF-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC1=CN=N[N]1 ACXMTAJLYQCRGF-PBFPGSCMSA-N 0.000 claims description 2
- 229960002420 cefatrizine Drugs 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 229940106164 cephalexin Drugs 0.000 description 11
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 229960004621 cinoxacin Drugs 0.000 description 3
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 3
- 244000000058 gram-negative pathogen Species 0.000 description 3
- 244000000059 gram-positive pathogen Species 0.000 description 3
- -1 pivaloyloxymethyl ester Chemical class 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001103259 Baltimora Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical class N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT28934/78A IT1119708B (it) | 1978-10-20 | 1978-10-20 | Impiego di beta-chetoacidi eterociclici azotati come inibitori del trasferimento di fattori genetici di resistenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE879489A true BE879489A (fr) | 1980-02-15 |
Family
ID=11224798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/197705A BE879489A (fr) | 1978-10-20 | 1979-10-18 | Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5573612A (enExample) |
| BE (1) | BE879489A (enExample) |
| IT (1) | IT1119708B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69019395D1 (de) | 1989-02-21 | 1995-06-22 | Banyu Pharma Co Ltd | Zusammensetzung gegen Mikroben. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU167910B (enExample) * | 1972-11-22 | 1976-01-28 | ||
| JPS5745219B2 (enExample) * | 1972-12-18 | 1982-09-27 | ||
| JPS5750783B2 (enExample) * | 1974-02-07 | 1982-10-28 |
-
1978
- 1978-10-20 IT IT28934/78A patent/IT1119708B/it active
-
1979
- 1979-10-17 JP JP13412479A patent/JPS5573612A/ja active Granted
- 1979-10-18 BE BE0/197705A patent/BE879489A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6250448B2 (enExample) | 1987-10-24 |
| JPS5573612A (en) | 1980-06-03 |
| IT7828934A0 (it) | 1978-10-20 |
| IT1119708B (it) | 1986-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0180798B1 (ko) | 결정성 페니실린 유도체, 그의 제법 및 용도 | |
| Chain et al. | An antibacterial substance produced by Penicillium claviforme | |
| US4956179A (en) | Antibacterial combination of penicillin and cephalosporin | |
| WO2006120494A1 (fr) | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol | |
| FR2498931A1 (fr) | Medicament constitue par l'acide ethyl-1 fluoro-6 piperazinyl-7 oxo-4 dihydro-1,4 quinoleine-3 carboxylique et ses sels d'addition d'acides non toxiques pharmaceutiquement acceptables | |
| US4386070A (en) | Pharmaceutical compositions endowed with an antibacterial activity and their use in the treatment of infections due to gram-positive and gram-negative pathogens | |
| JP7194115B2 (ja) | 新規なデプシペプチドおよびその使用 | |
| BE879489A (fr) | Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation | |
| Panwalker et al. | Efficacy of cinoxacin in urinary tract infections | |
| Frolov et al. | Expanding the Variety of Pyridinium‐Based Bis‐QACs with Antimicrobial Properties: Investigation into Linker Structure‐Activity Correlation | |
| EP0536035A1 (fr) | Dérivés de benzonaphtyridine-1,8 et compositions anti-microbiennes | |
| US3694447A (en) | Complexes of phosphanilic acid and 9-amino-3-nitroacridine | |
| BE818335R (fr) | Composition antibacterienne et procede | |
| CN108685911B (zh) | 2-[(4-叔丁基噻唑-2-基)亚氨基]噻唑啉-4-酮在制药中的应用 | |
| US4071628A (en) | Synergistic antimicrobial mixtures | |
| JPH06505259A (ja) | 複素環式化合物 | |
| LU87604A1 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle)piperazine,un procede pour leur preparation et compositions therapeutiques en contenant | |
| FR2591598A1 (fr) | Nouveaux derives d'acide ceph-3-em-4-carboxylique, leur preparation et medicaments les contenant | |
| US3407195A (en) | 4-methyl-1-(5-nitrofurfurylideneamino)-2-imidazolidinone | |
| JPH01221302A (ja) | 工業用殺菌剤及び殺菌方法 | |
| CN109928880A (zh) | 一种紫苏氧基羰基丙酸乙酯及其应用 | |
| BE825937A (fr) | Compositions antibacteriennes comprenant un compose de cephalosporine et un compose de penicilline | |
| JPS6365641B2 (enExample) | ||
| RU2229473C2 (ru) | Применение этилового эфира 5-бром-3,4-дигидрокси-2-карбамоил-6-оксо-6-фенил-2,4-гексадиеновой кислоты в качестве средства, обладающего антимикробной активностью | |
| BE898603A (fr) | Esters de type penem, procede pour les preparer, medicament les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: AUSONIA FARMACEUTICI S.R.L. Effective date: 19891031 |